MOTS-c is not FDA-approved. Current 503A regulatory records do not establish an ordinary retail bulk-compounding route [9]. The MOTS-c guide covers the science; research authorization, substance eligibility and drug approval are different determinations.
No, MOTS-c is not FDA-approved for any use
The reviewed FDA assessment and current 503A regulation do not establish ordinary retail bulk-compounding eligibility. That is different from appropriately authorized clinical investigation [9] [10].
| Version | FDA-approved? | Route under FDA rules | What it means for you |
|---|---|---|---|
| Approved drug | None exists | No application has been approved | No prescription brand to ask for |
| 503A compounded MOTS-c | No | No monograph, not in an approved drug, not on the 503A bulks list | No ordinary bulk eligibility established by reviewed records |
| Clinic "MOTS-c programs" | No | The reviewed records do not establish ordinary bulk eligibility | Marketing does not change the status |
| "Research use only" vials | No | Research label alone does not establish human-use authorization | Identify the exact product, oversight and authorization; a seller label does not supply them |
Sources: FDA briefing on MOTS-c, July 2026; FDA safety-risks page (April 2026); FDA 503A categories list.
Current records do not establish ordinary bulk-compounding eligibility
A 503A pharmacy can compound from a raw ingredient only if it has a USP or NF monograph, is part of an FDA-approved drug, or is on FDA's 503A bulks list [6]. FDA's briefing rules out the first two in one sentence:
There is no applicable United States Pharmacopeia (USP) or National Formulary (NF) drug substance monograph for MOTS-c (free base) or its acetate form, and neither is a component of an FDA-approved drug.[3]
MOTS-c is not on the bulks list, and it is not in Category 1 of FDA's interim policy, the category FDA leaves alone while it evaluates a substance. It sits in FDA's table of substances whose nominations were withdrawn [5]. The same is true of BPC-157, reviewed at the same meeting; see is BPC-157 FDA-approved.
FDA's own review said the criteria weigh against listing it
FDA's reviewers wrote that "the evaluation criteria weigh against placing MOTS-c (free base) or MOTS-c acetate" on the 503A bulks list [3]. Their reasons were poor characterization of the substance, no clinical studies in people and no data to judge safety.
On human data, the briefing is categorical: "The nomination did not include, and FDA has not identified, any clinical studies or human exposure data for MOTS-c via any route of administration" [3].
FDA's two documents differ on what was reviewed. The meeting page lists the uses reviewed as obesity and osteoporosis [4]. A briefing footnote says FDA did not evaluate the nominated uses, which included obesity, insulin resistance and longevity, because the nomination lacked enough information [3]. Either way, no use was supported by a human study.
Reliable human treatment-safety rates are unestablished
The reviewed evidence does not establish reliable human treatment-safety rates. FDA’s briefing identifies missing safety and PK data; its FAERS searches through March 2025 found no reports. Those dated searches are not a current incidence estimate [3].
Anecdotal symptom lists do not establish product identity, causation or frequency. FDA’s primary assessment identifies uncertainty and potential manufacturing/immune risks; the current protocol plans safety assessments but supplies no results [8].
A placebo-controlled trial of MOTS-c itself, in an estimated 120 adults with prediabetes and excess weight, was registered in 2026 and was recruiting as of this update [2]. That protocol has no posted treatment results; endogenous measurements in people answer different questions.
The animal results behind the interest, such as lighter weight in mice on a high-fat diet, are covered in the guide. Appetite and other day-to-day questions are in whether MOTS-c is safe.
Interpret approval, policy and research separately
- MOTS-c is not approved, so no prescription brand exists.
- A clinic program does not establish an applicable compounding exemption or research authorization.
- A “research use only” label and purity claim do not establish authorization for human treatment.
- Press releases from clinics announcing MOTS-c programs are marketing. They are not FDA statements.
- In tested sport it is banned outright: WADA's Prohibited List names it under S4.4.1, metabolic modulators [7].
Whether you can buy MOTS-c legally anywhere is covered in can you buy MOTS-c legally. If a provider offers it, ask what the product is and which pharmacy made it. Those are the same questions behind every provider check on this site.
The current NCT07505745 record lists 120 estimated participants, recruiting at a site in China, with no posted results. Structured primary outcomes are insulin sensitivity at 12 weeks and adverse events through 16 weeks. Its detailed narrative also names body weight and waist circumference, although those are absent from the structured outcome list. That reporting difference prevents a categorical claim that weight will not be measured [8].